Searchable abstracts of presentations at key conferences on calcified tissues

ba0004p20 | (1) | ICCBH2015

Bone mineral density in patients with autosomal recessive osteopetrosis after hematopoietic cell transplantation

Petryk Anna , Polgreen Lynda E , Dengel Donald R , Defor Todd E , Orchard Paul

Objectives: Autosomal recessive osteopetrosis (OP) is a rare metabolic bone disease characterized by impaired osteoclast function resulting in defective bone resorption and generalized high bone mineral density (BMD). Excessive bone compromises bone marrow space, leading to marrow failure. The infantile malignant form is typically fatal within the first decade of life. The intermediate form presents later during childhood. Currently, the only potential curative therapy for OP ...

ba0005p339 | Osteoporosis: pathophysiology and epidemiology | ECTS2016

High prevalence of reduced bone mineral density and undertreatment of osteoporosis in patients with systemic sclerosis

Spanjer Moon J , Bultink Irene E M , Voskuyl Alexandre E , Lems Willem F

Purpose: Systemic sclerosis (SSc) is a rare inflammatory rheumatic disease that has been associated with an increased risk of low bone mineral density (BMD). However, data on risk factors associated with bone loss in SSc are scarce. The objective of this study was to investigate the prevalence of and the risk factors for low BMD in patients with SSc.Methods: Cross-sectional data of 61 patients with SSc were collected. BMD in the lumbar spine, total hip a...

ba0005p102 | Cancer and bone: basic, translational and clinical | ECTS2016

Inhibition of mTOR signaling by everolimus has concurrent anti-tumor and bone-protective effects in murine osteolytic cancer models

Browne Andrew , Kubasch Marie Luise , Gobel Andy , Hadji Peyman , Chen David , Rauner Martina , Rachner Tilman , Hofbauer Lorenz

Clinical data suggest that the mTOR inhibitor everolimus may have bone protective effects in addition to its anti-tumor effects in women with ER+/HER2− metastatic breast cancer receiving hormone-ablative therapies. Based on these findings, we tested the hypothesis, whether everolimus exerts concurrent anti-tumor effects while protecting the skeleton in murine models. Thus, we assessed bone metabolism and anti-tumor effects in osteolytic cancer models upon exposure to eve...

ba0005p208 | Cell biology: Osteocytes, mechanobiology | ECTS2016

Transgene expression by Dmp1 promoter fragments occurs in various organs

Saito Hiroaki , Taipaleenmaki Hanna , Al-Jazzar Ahmed , Gasser Andreas , Javaheri Behzad , Scudamore Cheryl , Bellido Teresita , Pitsillides Andrew A , Hesse Eric

Analysis of osteocyte function often uses promoter elements of osteocyte-specific genes i.e. SOST or Dentin-matrix-protein 1 (Dmp1) to overexpress genes or the Cre-recombinase for conditional deletion studies. However, evidence suggests that these promoters may not be osteocyte-specific, which would be critical for subsequent data interpretation. To investigate the selectivity of supposedly osteocyte-specific in vivo models, we crossed the 8kb-Dmp1-Cre mice (i) with A...

ba0005p401 | Osteoporosis: treatment | ECTS2016

Two-fold regional variation in initiation of anti-osteoporosis medication after hip fracture in the UK

Shah Anjali , Prieto-Alhambra Daniel , Hawley Samuel , Delmestri Antonella , Lippett Janet , Cooper Cyrus , Judge Andrew , Javaid Kassim

Objective: Describe UK regional variation in prescription of anti-osteoporosis drug therapy before and after a primary hip fracture during 1999–2013.Materials and Methods: We used primary care data (Clinical Practice Research Datalink) to identify patients with a hip fracture and primary-care prescriptions of any anti-osteoporosis drugs (bisphosphonates, strontium, denosumab, oestrogen therapy, SERMS, teriparatide) prior to primary hip fracture and ...

ba0005p465 | Other diseases of bone and mineral metabolism | ECTS2016

Tracking inflammation in mouse model of fibrodysplasia ossificans progressiva prior to the detection of heterotopic ossification as a potential biomarker

Nannuru Kalyan , Jimenez Johanna , Huang Lily , Wen Xialing , Wang Lili , Xie LiQin , Idone Vincent , Murphy Andrew , Hatsell Sarah , Economides Aris

Fibrodysplasia ossificans progressiva (FOP) is a rare debilitating genetic disease characterized by abnormal progressive heterotopic endochondrial ossification of soft tissues. FOP results from mutations in the intracellular domain of the type I BMP receptor ACVR1 (ALK2) the most common of which is R206H. FOP mutations alter the sensitivity of ACVR1 to Activin A from an antagonist to an agonist. We have previously shown that Activin A is necessary and sufficient for driving he...

ba0007p140 | (1) | ICCBH2019

Safety and effectiveness of stoss therapy in children

Fiscaletti Melissa , Tannous Paul , Wood Nicholas , Gunasekera Hasantha , Zurynski Yvonne , Biggins Andrew , Kilo Tatjana , Hayes Evan , Munns Craig

Objectives: Pediatric vitamin D (25-hydroxyvitamin D - 25OHD) deficiency can lead to nutritional rickets and extra-skeletal complications. Compliance with daily therapy can be difficult, making high dose, short-term vitamin D (stoss) therapy attractive to correct vitamin D deficiency. We compared the effectiveness and safety of standard versus stoss therapy in treating childhood 25OHD deficiency.Study design: Children aged 2–16 years with 25OHD &#60...

ba0007p141 | (1) | ICCBH2019

Hypercalcaemia and osteonecrosis of the jaw in association with denosumab use in the paediatric population

Wall Christie-Lee , Pacey Verity , Gray Kelly , McGee Richard , Fiscaletti Melissa , Poon Myra , Biggin Andrew , Munns Craig

Background: Denosumab (DMAB) is used in adults for the treatment of osteoporosis, giant cell tumour of bone, and cancer metastases. There are little data on paediatric use with clinical decision making reliant on adult data and clinical experience.Presenting problem: We have treated 33 children with DMAB: Perthes disease (n=9), avascular necrosis (n=17), osteoporosis (n=1), aneurysmal bone cyst (n=4) and giant cell tum...